INS and type 2 diabetes mellitus: A recent investigation demonstrated that patients with T2DM experienced a decrease in HbA1c levels and insulin dose at the 6-month mark following treatment and after receiving a combination of intravenous and intrapancreatic endovascular injection of umbilical cord-derived mesenchymal stem cells (UC-MSCs) with a 5-day interval.